NeuroMed

Company Overview

Snapshot

Founded in January 2005, NeuroMed operates with 1-10 employees. The company has raised $1 million across one funding round. NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.

Business overview

NeuroMed Pharmaceuticals develops treatments for neurological degenerative diseases, focusing on its lead product, Yac-101. This potential treatment is based on specific metal chelation designed to prevent reactive oxygen species, maintain cytosolic calcium homeostasis, preserve mitochondrial function, and prevent cell membrane damage. The company operates within the pharmaceuticals sector, targeting the healthcare and life sciences market with its drug discovery and development efforts.

Strategic signal

In October 2015, the U.S. arm of Sun Pharma's Taro acquired Zalicus Pharmaceuticals, which had previously integrated NeuroMed. This acquisition highlights the ongoing consolidation within the pharmaceutical industry, particularly for companies focused on biosimilar drugs and pain management candidates like Zalicus's Z944. For investors, this signals the potential for further M&A activity in the sector, driven by larger pharmaceutical entities seeking to expand their portfolios through strategic acquisitions of specialized drug developers.

Company Intelligence Q&A

What is NeuroMed's primary focus?

NeuroMed Pharmaceuticals focuses on developing treatments for neurological degenerative diseases, with its lead product, Yac-101, designed to address injuries involving neuro-degeneration.

When was NeuroMed acquired?

NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.

What is the core mechanism of NeuroMed's Yac-101 treatment?

Yac-101 is based on specific and differentiating metal chelation, which aims to prevent reactive oxygen species, maintain cytosolic calcium homeostasis, preserve mitochondrial function, and prevent cell membrane damage induced by lipid peroxidation.

What was the total capital raised by NeuroMed?

NeuroMed raised a total of $1 million across one funding round.

What happened to Zalicus Pharmaceuticals, which integrated NeuroMed?

In October 2015, the U.S. arm of Sun Pharma's Taro acquired Zalicus Pharmaceuticals for $3.8 million in cash and a $3.8 million limited recourse note. Zalicus had previously integrated NeuroMed and was a subsidiary of Epirus Biopharmaceuticals.